International Relations9 October 20265 min read
India tells UN meeting it can bridge North-South divide on pandemic agreement
At the United Nations High-Level Meeting in New York in September 2026, India delivered its official intervention on the Political Declaration on Pandemic Prevention, Preparedness and Response, an instrument aligned with the WHO Pandemic Agreement. With negotiations on the Pathogen Access and Benefit-Sharing (PABS) System unresolved, India is seeking to bridge the divide between high-income countries and low- and middle-income countries (LMICs).
Why the agreement is not yet in force
The WHO Pandemic Agreement is a legally binding treaty negotiated under Article 19 of the WHO Constitution. It was adopted in May 2025 but has not entered into force. The Intergovernmental Negotiating Body, comprising over 190 WHO member states, negotiated it. It is only the second binding convention under Article 19, after the 2003 WHO Framework Convention on Tobacco Control.
The draft was backed by 124 member states at the World Health Assembly, with no negative votes and 11 abstentions. Formal ratification is paused because member states are yet to finalise the PABS Annex. The annex will fix the exact percentage allocations of emergency countermeasures and the monetary contributions from private manufacturers. Negotiators remain divided over the share of real-time production that manufacturers must reserve for WHO distribution to LMICs.
What the agreement provides
The treaty follows the inequities of Covid-19. Advanced economies pre-booked and stockpiled vaccines, therapeutics and protective equipment, leaving LMICs with long delays. Voluntary mechanisms such as COVAX and the Access to Covid-19 Tools Accelerator (ACT-A) struggled with underfunding, bilateral supply contracts and export bans. Developing countries also shared pathogen genetic sequence data through platforms such as GISAID, while private companies used it to make vaccines without reciprocal access guarantees for the originating nations. Zoonotic threats such as H5N1, Mpox, Marburg and Ebola add to the case for a binding protocol.
Its main provisions are:
- the PABS System, under which rapid sharing of pathogen samples and sequences triggers a reserved quota of vaccines and diagnostics for WHO distribution;
- a One Health approach that integrates human, animal and environmental surveillance;
- technology transfer to expand regional manufacturing in Africa, Asia and Latin America;
- a Global Supply Chain and Logistics Network to prevent export curbs and secure raw materials;
- sustainable financing for laboratory, cold-chain and clinical capacity.
Concerns that remain
Developing countries had pushed for mandatory technology transfer, patent waivers and flexibilities under the Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement. The final text limits technology transfer to "mutually agreed terms", which makes it largely voluntary and could weaken it in an emergency.
On PABS, developing countries fear bio-piracy: that samples and data they share could be used to develop patented products without guaranteed access to the resulting vaccines and treatments. They also argue that One Health surveillance, including rural veterinary work, wildlife monitoring and laboratories, needs heavy investment and becomes an unfair burden without guaranteed international financing.
Sovereignty over public health, border controls and medical regulation is a further worry. The US has opposed stronger WHO authority, citing concerns over the PABS framework and interference with domestic commercial and national interests. Pharmaceutical companies argue that mandatory benefit-sharing and IP waivers could reduce incentives for costly research, and that price controls and forced technology sharing could disrupt supply chains.
India's position
India said global health cooperation must respect national sovereignty, domestic legal systems, regulatory approvals and policy space. It called for affordable and guaranteed access to essential medicines and diagnostics for developing countries, and for less vulnerable global supply chains. It also presented its Digital Public Infrastructure, including CoWIN, eSanjeevani and the Ayushman Bharat Digital Mission (ABDM), as scalable platforms for global health cooperation.
India cited its record under Vaccine Maitri, which supplied over 300 million Covid-19 vaccine doses to nearly 100 countries and UN peacekeeping missions and agencies, prioritising LMICs. It said it exported therapeutics, generic medicines, testing kits and active ingredients to more than 150 nations during supply disruptions. India acknowledged that it remains dependent on external sources for active pharmaceutical ingredients (APIs) and key starting materials, and said it supports resilient, diversified supply chains.
Options before India
The measures listed for India include working towards a balanced PABS compromise, given its role as both a data contributor and a generic manufacturer. They also include South-South partnerships in One Health surveillance and genomic sequencing, drawing on INSACOG, and offering CoWIN, Aarogya Setu and ABDM as open-source platforms.
India could also use the H20 Summit, scale the Global Initiative on Digital Health set up during its 2023 G20 Presidency, and coordinate within the Partners for Multilateralism coalition. At home, the measures include strengthening access and benefit-sharing under the Biological Diversity Act and accelerating Production Linked Incentive schemes for APIs, medical devices and biopharma. India would also seek to ensure the agreement safeguards the Doha Declaration on TRIPS and Public Health, which preserves the right to issue compulsory licences in emergencies.